The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34446442.
- Also identified by DOI 10.1126/science.abk2718.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Type III CRISPR-Cas immunity is widespread in prokaryotes and is generally mediated by multisubunit effector complexes. These complexes recognize complementary viral transcripts and can activate ancillary immune proteins. Here, we describe a type III-E effector from <i>Candidatus</i> “Scalindua brodae” (<i>Sb</i>-gRAMP), which is natively encoded by a single gene with several type III domains fused together. This effector uses CRISPR RNA to guide target RNA recognition and cleaves single-stranded RNA at two defined positions six nucleotides apart. <i>Sb</i>-gRAMP physically combines with the caspase-like TPR-CHAT peptidase to form the CRISPR-guided caspase (Craspase) complex, suggesting a potential mechanism of target RNA–induced protease activity to gain viral immunity.
Medical subject headings
- Bacteria
- Bacterial Proteins
- CRISPR-Associated Proteins
- CRISPR-Cas Systems
- Endoribonucleases
- Peptide Hydrolases